TY - JOUR
T1 - Treatment of genetically obese mice with the iminosugar N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin reduces body weight by decreasing food intake and increasing fat oxidation
AU - Langeveld, Mirjam
AU - van den Berg, Sjoerd A. A.
AU - Bijl, Nora
AU - Bijland, Silvia
AU - van Roomen, Cindy P.
AU - Houben-Weerts, Judith H.
AU - Ottenhoff, Roelof
AU - Houten, Sander M.
AU - van Dijk, Ko Willems
AU - Romijn, Johannes A.
AU - Groen, Albert K.
AU - Aerts, Johannes M.
AU - Voshol, Peter J.
PY - 2012
Y1 - 2012
N2 - Obesity and its associated conditions such as type 2 diabetes mellitus are major causes of morbidity and mortality. The iminosugar N-(5-adamantane-1-yl-methoxy-pentyl)deoxynojirimycin (AMP-DNM) improves insulin sensitivity in rodent models of insulin resistance and type 2 diabetes mellitus. In the current study, we characterized the impact of AMP-DNM on substrate oxidation patterns, food intake, and body weight gain in obese mice. Eight ob/ob mice treated with 100 mg/(kg d) AMP-DNM mixed in the food and 8 control ob/ob mice were placed in metabolic cages during the first, third, and fifth week of the experiment for measurement of substrate oxidation rates, energy expenditure, activity, and food intake. Mice were killed after 6 weeks of treatment. Initiation of treatment with AMP-DNM resulted in a rapid increase in fat oxidation by 129% (P = .05), a decrease in carbohydrate oxidation by 35% (P = .01), and a reduction in food intake by approximately 26% (P <.01) compared with control mice. Treatment with AMP-DNM decreased hepatic triglyceride content by 66% (P <.01) and, in line with the elevated fat oxidation rates, increased hepatic carnitine palmitoyl transferase la expression. Treatment with AMP-DNM increased plasma levels of the appetite-regulating peptide YY compared with control mice. Treatment with AMP-DNM rapidly reduces food intake and increases fat oxidation, resulting in improvement of the obese phenotype. These features of AMP-DNM, together with its insulin-sensitizing capacity, make it an attractive candidate drug for the treatment of obesity and its associated metabolic derangements. (C) 2012 Elsevier Inc. All rights reserved
AB - Obesity and its associated conditions such as type 2 diabetes mellitus are major causes of morbidity and mortality. The iminosugar N-(5-adamantane-1-yl-methoxy-pentyl)deoxynojirimycin (AMP-DNM) improves insulin sensitivity in rodent models of insulin resistance and type 2 diabetes mellitus. In the current study, we characterized the impact of AMP-DNM on substrate oxidation patterns, food intake, and body weight gain in obese mice. Eight ob/ob mice treated with 100 mg/(kg d) AMP-DNM mixed in the food and 8 control ob/ob mice were placed in metabolic cages during the first, third, and fifth week of the experiment for measurement of substrate oxidation rates, energy expenditure, activity, and food intake. Mice were killed after 6 weeks of treatment. Initiation of treatment with AMP-DNM resulted in a rapid increase in fat oxidation by 129% (P = .05), a decrease in carbohydrate oxidation by 35% (P = .01), and a reduction in food intake by approximately 26% (P <.01) compared with control mice. Treatment with AMP-DNM decreased hepatic triglyceride content by 66% (P <.01) and, in line with the elevated fat oxidation rates, increased hepatic carnitine palmitoyl transferase la expression. Treatment with AMP-DNM increased plasma levels of the appetite-regulating peptide YY compared with control mice. Treatment with AMP-DNM rapidly reduces food intake and increases fat oxidation, resulting in improvement of the obese phenotype. These features of AMP-DNM, together with its insulin-sensitizing capacity, make it an attractive candidate drug for the treatment of obesity and its associated metabolic derangements. (C) 2012 Elsevier Inc. All rights reserved
U2 - https://doi.org/10.1016/j.metabol.2011.05.013
DO - https://doi.org/10.1016/j.metabol.2011.05.013
M3 - Article
C2 - 21816446
SN - 0026-0495
VL - 61
SP - 99
EP - 107
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
IS - 1
ER -